Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 8/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24392682 | 0.93 | OPRK1 (0.34) | PDE2AOPRK1AKT1CYP1A2CYP2D6 | |
| SCHEMBL24392145 | 0.88 | SMYD3 (0.34) | PDE2AOPRK1AKT1HRH4 | |
| SCHEMBL24393217 | 0.85 | PDE2A (0.32) | PDE2A | |
| SCHEMBL24392146 | 0.82 | OPRK1 (0.36) | CSNK2A2CSNK2A1OPRK1AKT1 | |
| SCHEMBL24393334 | 0.78 | PDE2A (0.32) | PDE2A | |
| SCHEMBL24391888 | 0.76 | CHRM4 (0.42) | AKT1CYP2D6KIT | |
| SCHEMBL24391879 | 0.76 | PDE2A (0.34) | PDE2AKIT | |
| SCHEMBL24392190 | 0.75 | PDE2A (0.34) | PDE2AKIT | |
| SCHEMBL24391708 | 0.73 | PDE2A (0.33) | PDE2AKIT | |
| SCHEMBL24392137 | 0.72 | PDE2A (0.39) | PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | CSNK2A2 918/4885CSNK2A1 777/4885PDE2A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.